VBI-1901
Recurrent Glioblastoma (GBM)
Key Facts
Indication
Recurrent Glioblastoma (GBM)
Phase
Phase 2
Status
Active (Partial Clinical Hold)
Company
About VBI Vaccines
VBI Vaccines is a biopharmaceutical company founded on an innovative eVLP technology platform designed to elicit potent and broad immune responses. Its historical achievement was the U.S. approval and commercialization of PreHevbrio, a three-antigen hepatitis B vaccine, but the company has since ceased commercial operations and entered restructuring proceedings under the CCAA in Canada. Its current strategy is to preserve capital, review strategic alternatives, and advance its most promising clinical-stage assets in cytomegalovirus (CMV) prevention and glioblastoma (GBM) treatment through this period of financial distress.
View full company profile